Renforcer le système immunitaire contre les sarcomes.

Nov. 1, 2013 — A dual-pronged strategy using two experimental cancer drugs together could successfully treat a childhood cancer by inhibiting tumour growth and blocking off the escape routes it uses to become resistant to treatment, finds a new study.

Une stratégie en deux étapes et utilisant deux médicaments expérimentaux pourrait traiter avec succès un cancer chez l'enfant en inhibant la croissance de la tumeur et en bloquant les voies d'échappement qu'il utilise pour devenir résistant.

Scientists at The Institute of Cancer Research, London, found that combining two separate molecularly targeted therapies could stop processes driving growth in a cancer called rhabdomyosarcoma, a major cause of cancer death in children.

Les scientifiques ont découvert que combienr deux thérapies ciblées pourrait arrêter le processus qui donne lieu à ;a croissance du cancer nommé rhabdomyosarcome, une cause majeure de mort enfantine.

The drugs, called AZD8055 and AZD6244, block two different signalling pathways involved in cancer growth -- acting like road-blocks on two separate routes that cancers could otherwise use to evade treatment.

Les médicaments appelés AZD8055 et AZD6244 bloquent deux différents chemins cellulaires impliqués dans la croissance du cancer, il agit aussi comme barrière à deux routes séparées que les cancers pourraient utiliser pour échapper au traitement.

The study, published in Clinical Cancer Research, was funded by the NIHR Biomedical Research Centre for Cancer at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research (ICR), with additional funding from Cancer Research UK, The Royal Marsden Hospital Charitable Fund and the Chris Lucas Trust.

Rhabdomyosarcoma tumours can form anywhere in the body and resemble primitive muscle tissue. Despite advances in treatment options, there has been little improvement in outcome for patients with rhabdomyosarcoma in decades and they remain difficult to treat.

(Aug. 4, 2008) — Based on a pilot study in children with sarcoma, researchers at the National Institutes of Health (NIH) believe that immunotherapy could prove beneficial in treating high-risk forms of this cancer.

Se basant sur une étude sur les enfants avec des sarcomes, les chercheurs croient que l'immunothérapie pourrait être bénéfique pour traiter cette sorte de cancer à haut risque.

The researchers tested a novel dendritic vaccine as well as a standard flu vaccine to potentially strengthen the immune system post chemotherapy. Their findings, published in the August 1 issue of Clinical Cancer Research, show that although the dendritic vaccine they tested did not perform as well as hoped, children participating in the study responded well to the standard flu vaccine– suggesting that a strategy to bolster immune function in these patients holds promise for fighting their cancer.

Les chercheurs ont testé une nouvelle sorte de vaccin avec des cellules dendritiques aussi bien que des vaccins ordinaires contre le rhume dans le but de renforcer le système immunitaire. Même si le vaccin avec des cellules dendritiques n'a pas marché, celui contre le rhume ordinaire a eu des effets positifs. Cela suggère que ces patients pourrraient combattre leur cancer de cette manière.

Researchers also found that survival in these patients was at the higher end of what is generally seen with recurrent and/or metastatic Ewing's sarcoma (ESFT) or alveolar rhabdomyosarcoma (AR) – the two sarcomas tested in this single arm study. The 22 enrolled patients who did not receive immunotherapy had a 31 percent five-year overall survival, compared to 43 percent five-year survival in 30 patients who ultimately received the novel immunotherapy.

Les chercheurs ont trouvé que la survie de ces patients étaient plus élevée que ce qui se voyait habituellement avec le sarcome d'Ewing et le rhabdomyosarcome. Les deux sarcomas testés dans cette étude.